Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of LY2541546 in Women With Low Bone Mineral Density

Phase 2

Completed

Conditions: Osteoporosis

Interventions: Drug: LY2541546
Drug: Placebo

First Posted Date: 2010-06-15

Last Posted Date: 2019-09-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 154

Registration Number: NCT01144377

Locations: 🇱🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vilnius, Lithuania

A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms

Phase 3

Completed

Conditions: Benign Prostatic Hyperplasia
Enlarged Prostate

Interventions: Drug: Placebo
Drug: Tadalafil
Drug: Finasteride

First Posted Date: 2010-06-09

Last Posted Date: 2013-02-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 696

Registration Number: NCT01139762

Locations: 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Izmir, Turkey

A Study of LY2624587 in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Metastatic Cancer

Interventions: Drug: LY2624587

First Posted Date: 2010-06-09

Last Posted Date: 2012-01-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 56

Registration Number: NCT01139788

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States

A Study in Non Small Cell Lung Cancer

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Cisplatin
Drug: LY2603618

First Posted Date: 2010-06-09

Last Posted Date: 2018-05-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 76

Registration Number: NCT01139775

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain

A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib

Phase 3

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Biological: Ramucirumab DP (IMC-1121B)
Biological: Placebo
Other: BSC

First Posted Date: 2010-06-09

Last Posted Date: 2015-12-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 565

Registration Number: NCT01140347

Locations: 🇹🇭
ImClone Investigational Site, Hat Yai, Thailand

An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma

Phase 1

Completed

Conditions: Malignant Melanoma

Interventions: Biological: IMC-20D7S (Cohort 1A)
Biological: IMC-20D7S (Cohort 1B)
Biological: IMC-20D7S (Cohort 2B)
Biological: IMC-20D7S (Cohort 2A)
Biological: IMC-20D7S (Cohort 3A)
Biological: IMC-20D7S (Cohort 3B)
Biological: IMC-20D7S (Cohort 4A)

First Posted Date: 2010-06-04

Last Posted Date: 2019-06-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 27

Registration Number: NCT01137006

Locations: 🇺🇸
ImClone Investigational Site, New York, New York, United States

Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin

Phase 3

Terminated

Conditions: Hyperglycemia

Interventions: Drug: Human regular insulin
Drug: Insulin lispro
Drug: Insulin glargine

First Posted Date: 2010-06-03

Last Posted Date: 2012-11-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 16

Registration Number: NCT01136746

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States

Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Insulin Aspart 6 Day (6D)
Drug: Insulin Lispro 6 Day (6D)

First Posted Date: 2010-05-31

Last Posted Date: 2013-04-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 133

Registration Number: NCT01134107

Locations: 🇭🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zalaegerszeg, Hungary

A Study in Myeloproliferative Disorders

Phase 1

Completed

Conditions: Myeloproliferative Disorders
Polycythemia Vera
Thrombocythemia, Essential
Primary Myelofibrosis

Interventions: Drug: LY2784544

First Posted Date: 2010-05-31

Last Posted Date: 2018-04-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 80

Registration Number: NCT01134120

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States

A Safety Study of LY2886721 Single Doses in Healthy Subjects

Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Placebo
Drug: LY2886721

First Posted Date: 2010-05-28

Last Posted Date: 2019-09-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 40

Registration Number: NCT01133405

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beverly Hills, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy